Clinical Trial Update: Phase IV Clinical Study of Immunogenicity of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) [Phase 4]

View source ↗

Summary

Status update for a Phase IV trial evaluating the immunogenicity of the ACYW135 group meningococcal polysaccharide conjugate vaccine (CRM197 vector).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningitis

Drugs mentioned

• ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector)

Snippet

Sponsor: CanSino Biologics Inc. | Conditions: Epidemic Meningitis | Phase 4 | Status: ACTIVE_NOT_RECRUITING